Zhejiang Tianyu Pharmaceutical (SZ:300702) Xin Lang Cai Jing·2025-10-30 01:55Core Insights - Tianyu Co., Ltd. reported a total revenue of 2.287 billion yuan for Q3 2025, with a net profit attributable to shareholders of 221 million yuan, and a net cash inflow from operating activities of 215 million yuan, which represents a decrease of 117 million yuan or 35.13% compared to the same period last year [1] Financial Performance - The company's latest asset-liability ratio stands at 43.32%, ranking 91st among disclosed peers [3] - The latest gross profit margin is 39.14%, placing the company 77th among disclosed peers [3] - The return on equity (ROE) is reported at 5.94% [3] - The diluted earnings per share (EPS) is 0.63 yuan [3] - The total asset turnover ratio is 0.35 times, while the inventory turnover ratio is 0.75 times, ranking 108th among disclosed peers [3] Shareholder Structure - The number of shareholders is 15,200, with the top ten shareholders holding a total of 229 million shares, accounting for 65.94% of the total share capital [3] - The top ten shareholders and their respective holdings are as follows: - Lin Jie: 35.0 million shares - Tu Yongjun: 16.4 million shares - Jiangsu Zhaoxin Private Fund Management Co., Ltd.: 6.19 million shares - Tu Shanzeng: 2.33 million shares - Hong Kong Central Clearing Limited: 1.77 million shares - Zhejiang Tianyu Pharmaceutical Co., Ltd.: 1.02 million shares - Guotai Jiatai Stock Special Pension Product: 0.95 million shares - Ma Cheng: 0.87 million shares - Golden Eagle Fund: 0.68 million shares - Guotai Fund Management Co., Ltd.: 0.66 million shares [3]